Search results for "EPATOCARCINOMA"
showing 10 items of 33 documents
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
2021
Valentina Burgio,1 Massimo Iavarone,2 Giovanni Giuseppe Di Costanzo,3 Fabio Marra,4 Sara Lonardi,5,6 Emiliano Tamburini,7 Fabio Piscaglia,8 Gianluca Masi,9,10 Ciro Celsa,11 Francesco Giuseppe Foschi,12 Marianna Silletta,13 Daniela Caterina Amoruso,14 Margherita Rimini,15 Mariangela Bruccoleri,2 Raffaella Tortora,3 Claudia Campani,4 Caterina Soldà ,6 Massimo Giuseppe Viola,16 Antonella Forgione,8 Fabio Conti,12 Francesca Salani,9,10 Silvia Catanese,9,10 Carmelo Marco Giacchetto,17 Claudia Fulgenzi,13 Carmine Coppola,14 Pietro Lampertico,18 Antonio Pellino,6,19 Gabriele Rancatore,17 Giuseppe Cabibbo,17 Francesca Ratti,20 Federica Pedica,21 Angelo Della Corte,22 Massimo Colombo,18 Francesco De…
VALUTAZIONE RM E TC DELLA RISPOSTA AL TRATTAMENTO CON SORAFENIB IN PAZIENTI CIRROTICI CON EPATOCARCINOMA
IL PARTENOLIDE SENSIBILIZZA CELLULE DI EPATOCARCINOMA UMANO ALL' APOPTOSI INDOTTA DA TRAIL
2011
The synthetic cannabinoid WIN sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis by activating p8/CHOP/DR5 axis.
2010
In this paper we demonstrate that the synthetic cannabinoid WIN sensitizes human hepatocellular carcinoma (HCC) cells to apoptosis mediated by TNF-related apoptosis inducing ligand (TRAIL). The apoptotic mechanism induced by treatment with WIN/TRAIL combination involved the loss of the mitochondrial transmembrane potential and led to the activation of caspases. In HCC cells WIN treatment induced up-regulation of TRAIL death receptor DR5, an effect which seemed to be related to the increase in the level of p8 and CHOP, two factors implicated in cellular stress response and apoptosis. This relationship was suggested by the observation that the down-regulation of p8 or CHOP by specific siRNAs …
ALLELIC VARIANTS OF CYP2E1 GENE IN HEPATOCARCINOMA PATIENTS AND IN HEPATIC TUMOR CELL LINES
2011
Background and Aims: Hepatic enzyme CYP2E1 is involved in the metabolism of a number of exogenous and endogenous substances (i.e. ethanol, drugs and chemical carcinogens). Being polymorphic, CYP2E1 gene can give different xeno-metabolic capabilities in a population and it is well known that inadequate or no enzymatic deactivation of xenobiotics could induce an increased susceptibility to disease and cancer. In particular, one of the 5 -flanking region polymorphisms, able to differentiate CYP2E1 gene transcriptional activity, is caused by the appearance/disappearance of RsaI and PstI restriction sites, which generates two different alleles, namely *C1(Rsa+/Pst−) and *C2(Rsa−/Pst+) respective…
CYP2E1 VNTR polymorphisms and hepatocarcinoma: a gender-specific correlation
2010
Cytochrome P450 (CYP2E1) is often associate to susceptibility to alcohol-related diseases and various cancers, because of its role in the metabolism of multiple environmental xenobiotics. In the 5’- flanking region of the human CYP2E1 gene there are restriction fragment length polymorphism which are involved in the transcriptional regulation of the CYP2E1 gene. Recently a tandem repeat polymorphism (VNTR) in the 5’-flanking region of CYP2E1 was found. Because cytochrome P450 2E1 catalyzes the metabolic activation of pro-carcinogen and cytotoxic compound, we value the genetic distribution of this tandem repeat polymorphism in a healthy population, and in patients with hepatocellular carcinom…
POLIMORFISMI A SINGOLO NUCLEOTIDE ( SINGLE NUCLEOTIDE POLYMORPHISMS, SNPs) COME POSSIBILI MARCATORI GENETICI PER LA VALUTAZIONE DEL RISCHIO DI SVILUP…
Fattori di rischio influenzanti la sopravvivenza dei pazienti con epatocarcinoma su cirrosi sottoposti a diversi tipi di trattamento
2011
Trapianto di fegato per epatocarcinoma (HCC): integrazione di criteri clinici e radiologici con indicatori biologici per l’identificazione di pazient…
2011
EPATOMI MALIGNI DEL BAMBINO
1991
I tumori magli del fegato in età pediatrica sono rappresentati da due forme istologiche differenti: l'Epatoblastoma (EPB) e l'Epatocarcinoma (EPC). Gli Autori esaminano le caratteristiche cliniche, la stadiazione e gli aspetti terapeutici. Vengono altresì presentati i dati della letteratura ed i risultati del Protocollo Italiano di cura di queste neoplasie.